1. 20. Practical application of subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy – results from a multicenter, randomized, double-blind, placebo-controlled trial (The PATH Study). Issue 3 (March 2020) Authors: Schaik, I.N.; Bril, V.; Geloven, N.; Hartung, H.P.; Lewis, R.A.; Sobue, G.; Lawo, J.P.; Mielke, O.; Durn, B.L.; Cornblath, D.R.; Merkies, I.S.J.; Dimachkie, M.M. Journal: Clinical neurophysiology Issue: Volume 131:Issue 3(2020:Mar.) Page Start: e9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values. (June 2022) Authors: Arends, Samuel; Drenthen, Judith; van den Bergh, Peter; Franssen, Hessel; Hadden, Robert D.M.; Islam, Badrul; Kuwabara, Satoshi; Reisin, Ricardo C.; Shahrizaila, Nortina; Amino, Hiroshi; Antonini, Giovanni; Attarian, Shahram; Balducci, Claudia; Barroso, Fabio; Bertorini, Tulio; Binda, Davide; Bra... Journal: Clinical neurophysiology Issue: Volume 138(2022) Page Start: 231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.; Hartung, H.P.; Kappos, L.; Montalban, X.; Hughes, R.; Koendgen, H.; McNamara, J.; Pradhan, A.; Wormser, D.; Wolinsky, J.S. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P 1 Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis – analysis of the phase III, double-blind, double-dummy, interferon beta-1a- controlled OPERA I and OPERA II studies. Issue 10 (October 2017) Authors: Ziemssen, T.; Arnold, D.L.; Bar-Or, A.; Comi, G.; Hartung, H.P.; Hauser, S.L.; Kappos, L.; Lublin, F.; Selmaj, K.; Traboulsee, A.; Masterman, D.; Chin, P.; Garren, H.; Wolinsky, J.S. Journal: Clinical neurophysiology Issue: Volume 128:Issue 10(2017:Oct.) Page Start: e326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFNβ-1a–controlled OPERA I and OPERA II studies. Issue 10 (October 2017) Authors: Ziemssen, T.; Bar-Or, A.; Arnold, D.L.; Comi, G.; Hartung, H.P.; Hauser, S.L.; Lublin, F.; Selmaj, K.; Traboulsee, A.; Chin, P.; Fontoura, P.; Garren, H.; Masterman, D.; Kappos, L. Journal: Clinical neurophysiology Issue: Volume 128:Issue 10(2017:Oct.) Page Start: e326 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P 4 The impact of low affinity immunoglobulin gamma Fc region receptor III-A gene polymorphisms in neuromyelitis optica spectrum disorder and implications for treatment outcomes: results from the N-MOmentum study. (May 2022) Authors: Paul, F.; Bennett, J.; Weinshenker, B.; Kim, H.J.; Aktas, O.; Hartung, H.P.; Smith, M.; Rees, W.; She, D.; Katz, E.; Cree, B. Journal: Clinical neurophysiology Issue: Volume 137(2022) Page Start: e16 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. P23 Assessing the Long-term Outcomes of Ocrelizumab Treatment in Germany – CONFIDENCE Baseline Characteristics. Issue 4 (April 2020) Authors: van Hall, V.; Hartung, H.P.; Dirks, P.; Eggebrecht, J.; Hieke-Schulz, S.; Leemhuis, J.; Wormser, D.; Ziemssen, T. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e187 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Issue 4 (April 2020) Authors: Derfuss, T.; Weber, M.; Hughes, R.; Eggebrecht, J.; Wang, Q.; Sauter, A.; Koendgen, H.; Hauser, S.; Bar-Or, A.; Hartung, H.P. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. P60 Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.L.; Hartung, H.P.; Brochet, B.; Montalban, X.; Naismith, R.T.; Wolinsky, J.S.; Manfrini, M.; Garas, M.; Model, F.; Hubeaux, S.; Kappos, L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P61 Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial. Issue 8 (August 2019) Authors: Wolinsky, J.S.; Hartung, H.P.; Brochet, B.; Montalban, X.; Naismith, R.T.; Manfrini, M.; Garas, M.; Model, F.; Hubeaux, S.; Kappos, L.; Hauser, S.L. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e170 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗